


IN THE CLAIMS

Claims 1 through 27 canceled.

1 Claim 28 (new) A compound of the Formula (I)



2

I

3 wherein

4 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-
5 NR⁵R⁶, wherein


6 R⁵ and R⁶ independently from each other are hydrogen or
7 lower alkyl or together with the nitrogen atom to which they are
8 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
9 cyclic ring optionally containing one or more further nitrogen ,
10 sulfur and/or oxygen atoms;

11 R² is nitro or amino;

12 R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein

13 R⁷ and R⁸ independently from each other are hydrogen,
14 lower alkoxy, lower alkyl, or lower cycloalkyl, or together with
15 the nitrogen atom to which they are attached, form a 5- or 6-
16 membered, saturated or unsaturated heterocyclic ring optionally
17 containing one or more further nitrogen , sulfur and/or oxygen
18 atoms;
19 R⁴ is hydrogen or lower alkyl; and
20 the dotted lines have the following meanings:
21 if R³ and R⁴ are not present, the bond between positions C⁸ and C⁹ is
22 a single bond, and the bond between positions C⁸ and N⁷ is a double
23 bond;
24 if R³ and R⁴ are present, the bonds between positions C⁸ and C⁹ and
25 between positions C⁸ and N⁷ are single bonds; and
26 if R³ is present and R⁴ is missing, the bond between positions C⁸
27 and C⁹ is a double bond and the bond between positions C⁸ and N⁷ is a
28 single bond;
29 or a pharmaceutically acceptable salt thereof.

1 Claim 29 (new) A compound of the Formula (IA)



IA

3 wherein


4 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-
5 NR⁵R⁶, wherein

6 R⁵ and R⁶ independently from each other are hydrogen or
7 lower alkyl or together with the nitrogen atom to which they are
8 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
9 cyclic ring optionally containing one or more further nitrogen ,
10 sulfur and/or oxygen atoms; and

11 R² is nitro or amino;

12 or a pharmaceutically acceptable salt thereof.

1 Claim 30 (new) A compound of the Formula (IB)



IB

3 wherein

4 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-
5 NR⁵R⁶, wherein

6 R⁵ and R⁶ independently from each other are hydrogen or
7 lower alkyl or together with the nitrogen atom to which they are
8 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
9 cyclic ring optionally containing one or more further nitrogen ,
10 sulfur and/or oxygen atoms;


11 R² is nitro or amino;

12 R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein

13 R⁷ and R⁸ independently from each other are hydrogen,
14 lower alkoxy, lower alkyl, or lower cycloalkyl, or together with
15 the nitrogen atom to which they are attached, form a 5- or 6-
16 membered, saturated or unsaturated heterocyclic ring optionally

17 containing one or more further nitrogen , sulfur and/or oxygen
18 atoms; and
19 R⁴ is hydrogen or lower alkyl; or a pharmaceutically acceptable
20 salt thereof.

1 Claim 31 (new) A compound of the Formula (IC)



IC

3 wherein
4 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-
5 NR⁵R⁶, wherein
6 R⁵ and R⁶ independently from each other are hydrogen or
7 lower alkyl or together with the nitrogen atom to which they are
8 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
9 cyclic ring optionally containing one or more further nitrogen ,
10 sulfur and/or oxygen atoms;
11 R² is nitro or amino; and

12 R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein
13 R⁷ and R⁸ independently from each other are hydrogen,
14 lower alkoxy, lower alkyl, or lower cycloalkyl, or together with
15 the nitrogen atom to which they are attached, form a 5- or 6-
16 membered, saturated or unsaturated heterocyclic ring optionally
17 containing one or more further nitrogen, sulfur and/or oxygen
18 atoms; or a pharmaceutically acceptable salt thereof.

1 Claim 32 (new) The compound of the Formula (IA) defined
2 in claim 29 wherein R² is amino; or a pharmaceutically acceptable
3 salt thereof.

1 Claim 33 (new) The compound of the Formula (IB) defined
2 in claim 30 wherein R² is amino; or a pharmaceutically acceptable
3 salt thereof.

1 Claim 34 (new) The compound of the Formula (IC) defined
2 in claim 31 wherein R² is amino; or a pharmaceutically acceptable
3 salt thereof.

1 Claim 35 (new) The compound of the Formula (IB) defined
2 in claim 30 wherein R¹ is methyl or cyano; R² is amino; R³ is lower
3 alkanoyl or -CONR⁷R⁸; R⁷ is hydrogen; R⁸ is lower alkyl, lower

alkoxy, or lower cycloalkyl; and R⁴ is hydrogen or methyl; or a pharmaceutically acceptable salt thereof.

Claim 36 (new) The compound of the Formula (IB) defined in claim 35 which is 7-acetyl- -5-(4-amino-3-methyl-phenyl)-7, 8-dihydro-8-methyl--9H-1,3- -dioxolo[4,5-h][2,3]benzodiazepine; or a pharmaceutically acceptable salt thereof.

Claim 37 (new) The compound of the Formula (IB) defined in claim 35 which is selected from the group consisting of:

5-(3-methyl-4-amino-phenyl)-7-propionyl-7, 8-dihydro-8-methyl-9H-1, 3-dioxolo[4,5-h][2,3]benzodiazepine;

5-(4-amino-3-methyl-phenyl)-7-(N-cyclopropyl-carbamoyl)-7, 8-dihydro-8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;

5-(4-amino-3-methyl-phenyl)-7-(N-methoxy-carbamoyl)-7,8-dihydro-8-methyl-9H-1, 3-dioxolo[4,5-h][2,3]benzodiazepine;

5-(4-amino-3-methyl-phenyl)-7-(N-methyl-carbamoyl)-7,8-dihydro-8-methyl-9H-1, 3-dioxolo[4,5-h][2, 3]benzodiazepine;

5-(4-amino-3-methyl-phenyl)-7-acetyl-8-cyano-7, 8-dihydro-8-methyl-

16 -9H-1, 3-dioxolo[4,5-h][2,3]benzodiazepine; and
17 5-(4-amino-3-methyl-phenyl)-8-cyano-7-propionyl-7,
18 8-dihydro--8-methyl-
19 -9H-1, 3-dioxolo[4,5-h][2,3]benzodiazepine; or a pharmaceutically
20 acceptable salt thereof.

1 Claim 38 (new) The compound of the Formula (IC) defined
2 in claim 31 wherein R¹ is methyl; R² is amino; R³ is lower alkanoyl
3 or -CONR⁷R⁸; R⁷ is hydrogen; and R⁸ is lower alkyl, lower alkoxy, or
4 lower cycloalkyl; or a pharmaceutically acceptable salt thereof.


1 Claim 39 (new) The compound of the Formula (IC) defined
2 in claim 38 selected from the group consisting of:
3 7-acetyl-5-(4-amino-3-methyl-phenyl)-8-methyl-7 H-1,
4 3-dioxolo[4,5-h][2,3]- benzodiazepine;
5 7-(N-methyl-carbamoyl)-5-(4-amino-3-methyl-phenyl)-8-methyl-7H-1,3-
6 dioxolo- [4,5-h][2,3]benzodiazepine; and
7 7-(N-cyclopropyl-carbamoyl)-5-(4-amino-3-methyl-phenyl)-8--methyl-7
8 H-1,3-dioxolo- [4,5-h][2,3]benzodiazepine; or a pharmaceutically
9 acceptable salt thereof.

1 Claim 40 (new) The compound of the Formula (IA) defined
2 in claim 29 wherein R¹ is formyl, carboxy, cyano, -CH=NOH, -

3 CH=NNHCONH₂ or -CO-NR⁵R⁶, or a pharmaceutically acceptable salt
4 thereof.

1 Claim 41 (new) The compound of the Formula (IA) defined
2 in claim 40 which is 5-(4-amino-3-methyl-phenyl)-8-(semicarbazono-
3 methyl)-9H-1,3-dioxolo-[4,5-H][2,3]benzodiazepine or a pharmaceuti-
4 cally acceptable salt thereof.

1 Claim 42 (new) A process for the preparation of a
2 compound of the Formula (I)



4 wherein

5 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-
6 NR⁵R⁶, wherein

7 R⁵ and R⁶ independently from each other are hydrogen or
8 lower alkyl or together with the nitrogen atom to which they are

9 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
10 cyclic ring optionally containing one or more further nitrogen ,
11 sulfur and/or oxygen atoms;

12 R² is nitro or amino;

13 R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein

14 R⁷ and R⁸ independently from each other are hydrogen,
15 lower alkoxy, lower alkyl, or lower cycloalkyl, or together with
16 the nitrogen atom to which they are attached, form a 5- or 6-
17 membered, saturated or unsaturated heterocyclic ring optionally
18 containing one or more further nitrogen , sulfur and/or oxygen
19 atoms;

20 R⁴ is hydrogen or lower alkyl; and

21 the dotted lines have the following meanings:

22 if R³ and R⁴ are not present, the bond between positions C⁸ and C⁹ is
23 a single bond, and the bond between positions C⁸ and N⁷ is a double
24 bond;

25 if R³ and R⁴ are present, the bonds between positions C⁸ and C⁹ and
26 between positions C⁸ and N⁷ are single bonds; and


27 if R³ is present and R⁴ is missing, the bond between positions C⁸
28 and C⁹ is a double bond and the bond between positions C⁸ and N⁷ is a
29 single bond;

30 or a pharmaceutically acceptable salt thereof; which comprises:

31 a) for the preparation of

32 8-formyl-5-(3-methyl-4-nitro--phenyl)-9H-1,3- dioxolo[4,5-h]-

33 -[2,3]benzodiazepine of the Formula (III)




III

34 oxidizing

35 8-methyl-5-(4-nitro-3-methyl-phenyl)-9H-1,3--dioxolo[4,5-h][2,3]ben


36 zodiazepine of the Formula (II)



II


38 or

- 40 b) for the preparation of
41 5-(3-methyl-4-nitro-phenyl)--9H-1,3-dioxolo-
42 [4,5-h][2,3]benzodiazepine-8-carboxylic acid of the Formula (IV)



IV

- 44 oxidizing the
45 8-formyl-5-(3-methyl-4-nitro-phenyl)-9H-1,3--dioxolo[4,5-h][2,3]ben
46 zodiazepine;
47 or c) for the preparation of a compound of the Formula (V)




V

49 wherein Y is a leaving group, reacting the compound of the Formula
50 IV with a compound capable of introducing group Y;

51 or

52 d) for the preparation of the compound of the Formula

53 (VI)




VI

55 wherein R⁵ and R⁶ are as defined above, reacting the carboxylic acid
56 of the Formula (IV) or a reactive derivative thereof of the
57 Formula (V) with an amine of the Formula HNR⁵R⁶;
58 or

59

e) for the preparation of a compound of the Formula (VII)

60



VII

61

wherein R' is cyano, -CH=NOH or -CH=NNHCONH₂, converting in the compound of the Formula (III) the formyl group into an R' group;

62


63 or

64

f) for the preparation of a compound of the Formula

65 (VIII)

66




VIII

67 saturating the C8-N7 double bond of the compound of the Formula
68 (VII) by addition or reduction;

69 or


70 g) for the preparation of a compound of the Formula (IX)



IX

72 wherein R^{3'} is lower alkanoyl), reacting a compound of the Formula
73 (VIII) with a compound capable of introducing a lower alkanoyl
74 group;
75 or

h) for the preparation of a compound of the Formula (X)




X

wherein Y is a leaving group and R¹ and R⁴ are as stated above,
reacting a compound of the Formula (VIII) with a compound capable
of introducing the -COY group;

or

i) for the preparation of a compound of the Formula (XI)




XI

Atty's 22096

84 wherein R^1 , R^4 , R^7 and R^8 are as stated above, reacting a compound of
85 the Formula (X) or the corresponding free carboxylic acid thereof
86 with an amine of the Formula HNR^7R^8 ;

87 or

88 j) for the preparation of a compound of the Formula (XII)




89

90 wherein Z is a leaving group, reacting the compound of the Formula
91 (II) with a compound capable of introducing the -COZ group;
92 or

93 k) for the preparation of a compounds of the Formula

94 (XIII)



XIII

96 wherein R^7 and R^8 are as stated above, reacting a compound of the
97 Formula (XII) with an amine of the Formula HNR^7R^8 ;

98 or

99 1) for the preparation of a compound of the Formula (I),
100 wherein R^2 is amino, reducing the corresponding compound of the
101 Formula (I), wherein R^2 is nitro; and, if desired, converting a
102 compound of the Formula (I) into a pharmaceutically acceptable acid
103 addition salt thereof or setting free a compound of the Formula (I)
104 from a salt.


1 Claim 43 (new) Process according to process 1) defined
2 in Claim 42 which comprises reducing as the compound of the Formula

(I), a compound of the Formulae (II), (VII), (IX), (XI), (XII) or (XIII).

Claim 44 (new) Process according to Claim 43 which comprises carrying out the reduction by using stannous(II)chloride, sodium dithionite or by means of catalytic hydrogenation.

Claim 45 (new) Process according to Claim 44 in which the reduction is carried out by catalytic hydrogenation and which comprises using a Raney-nickel, palladium or platinum catalyst, and a hydrogen source selected from the group consisting of hydrogen, hydrazine, hydrazine hydrate, formic acid, trialkyl ammonium formate and an alkali formate.

Claim 46 (new) A process for preparing a compound of the Formula (I)



I.

4 wherein

5 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂ or -CO-
6 NR⁵R⁶, wherein

7 R⁵ and R⁶ independently from each other are hydrogen or
8 lower alkyl or together with the nitrogen atom to which they are
9 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
10 cyclic ring optionally containing one or more further nitrogen ,
11 sulfur and/or oxygen atoms;

12 R² is amino;

13 R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein

14 R⁷ and R⁸ independently from each other are hydrogen,
15 lower alkoxy, lower alkyl, or lower cycloalkyl, or together with
16 the nitrogen atom to which they are attached, form a 5- or 6-
17 membered, saturated or unsaturated heterocyclic ring optionally
18 containing one or more further nitrogen , sulfur and/or oxygen
19 atoms;

20 R⁴ is hydrogen or lower alkyl; and

21 the dotted lines have the following meanings:


22 if R³ and R⁴ are not present, the bond between positions C⁸ and C⁹ is
23 a single bond, and the bond between positions C⁸ and N⁷ is a double
24 bond;

25 if R³ and R⁴ are present, the bonds between positions C⁸ and C⁹ and
26 between positions C⁸ and N⁷ are single bonds; and

Atty's 22096

2:

27 if R^3 is present and R^4 is missing, the bond between positions C^8
 28 and C^9 is a double bond and the bond between positions C^8 and N^7 is a
 29 single bond;
 30 or a pharmaceutically acceptable salt thereof; which comprises the
 31 step of reducing a compound of the Formula (I)



I

32

33 wherein


34 R^2 is nitro and R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and the dotted lines are as

35 defined above

36 with stannous(II) chloride, sodium dithionite or by catalytic

37 hydrogenation.

1 Claim 47 (New) A pharmaceutical composition for antago-
2 nizing an AMPA/cainate receptor which comprises a therapeutically
3 effective amount of a compound of the Formula (I)



I

5 wherein

6 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-
7 NR⁵R⁶, wherein

8 R⁵ and R⁶ independently from each other are hydrogen or
9 lower alkyl or together with the nitrogen atom to which they are
10 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
11 cyclic ring optionally containing one or more further nitrogen ,
12 sulfur and/or oxygen atoms;

13 R² is nitro or amino;

14 R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein

15 R⁷ and R⁸ independently from each other are hydrogen,
16 lower alkoxy, lower alkyl, or lower cycloalkyl, or together with

the nitrogen atom to which they are attached, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atoms;

R⁴ is hydrogen or lower alkyl; and

the dotted lines have the following meanings:

if R³ and R⁴ are not present, the bond between positions C⁸ and C⁹ is a single bond, and the bond between positions C⁸ and N⁷ is a double bond;


if R³ and R⁴ are present, the bonds between positions C⁸ and C⁹ and between positions C⁸ and N⁷ are single bonds; and

if R³ is present and R⁴ is missing, the bond between positions C⁸ and C⁹ is a double bond and the bond between positions C⁸ and N⁷ is a single bond;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable inert carrier.

Claim 48 (new) A method of treating a mammalian subject in need of antagonization of an AMPA/cainate receptor which comprises the step of administering to said mammalian subject a therapeutically effective amount of a compound of the Formula (I) as defined in claim 28.

1 Claim 49 (new) A pharmaceutical composition for treating
2 epilepsy which comprises a therapeutically effective amount of a
3 compound of the Formula (I)



I

5 wherein

6 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-
7 NR⁵R⁶, wherein

8 R⁵ and R⁶ independently from each other are hydrogen or
9 lower alkyl or together with the nitrogen atom to which they are
10 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
11 cyclic ring optionally containing one or more further nitrogen ,
12 sulfur and/or oxygen atoms;

13 R² is nitro or amino;

14 R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein


15 R⁷ and R⁸ independently from each other are hydrogen,
16 lower alkoxy, lower alkyl, or lower cycloalkyl, or together with

17 the nitrogen atom to which they are attached, form a 5- or 6-
18 membered, saturated or unsaturated heterocyclic ring optionally
19 containing one or more further nitrogen , sulfur and/or oxygen
20 atoms;
21 R⁴ is hydrogen or lower alkyl; and
22 the dotted lines have the following meanings:
23 if R³ and R⁴ are not present, the bond between positions C⁸ and C⁹ is
24 a single bond, and the bond between positions C⁸ and N⁷ is a double
25 bond;
26 if R³ and R⁴ are present, the bonds between positions C⁸ and C⁹ and
27 between positions C⁸ and N⁷ are single bonds; and
28 if R³ is present and R⁴ is missing, the bond between positions C⁸
29 and C⁹ is a double bond and the bond between positions C⁸ and N⁷ is a
30 single bond;
31 or a pharmaceutically acceptable salt thereof, and a pharmaceuti-
32 cally acceptable inert carrier.

1 Claim 50 (new) A method of treating a mammalian subject
2 in need of treatment for epilepsy which comprises the step of
3 administering to said mammalian subject a therapeutically effective
4 amount of a compound of the Formula (I) as defined in claim 28.

1 Claim 51 (new) A pharmaceutical composition for treating
2 or preventing stroke, Parkinson's disease, multiple sclerosis, or

amyotropic lateral sclerosis which comprises a therapeutically effective amount of a compound of the Formula (I)



wherein

R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-NR⁵R⁶, wherein

R⁵ and R⁶ independently from each other are hydrogen or lower alkyl or together with the nitrogen atom to which they are attached, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atoms;

R² is nitro or amino;


R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein

R⁷ and R⁸ independently from each other are hydrogen, lower alkoxy, lower alkyl, or lower cycloalkyl, or together with the nitrogen atom to which they are attached, form a 5- or 6-

19 membered, saturated or unsaturated heterocyclic ring optionally
20 containing one or more further nitrogen , sulfur and/or oxygen
21 atoms;
22 R⁴ is hydrogen or lower alkyl; and
23 the dotted lines have the following meanings:
24 if R³ and R⁴ are not present, the bond between positions C⁸ and C⁹ is
25 a single bond, and the bond between positions C⁸ and N⁷ is a double
26 bond;
27 if R³ and R⁴ are present, the bonds between positions C⁸ and C⁹ and
28 between positions C⁸ and N⁷ are single bonds; and
29 if R³ is present and R⁴ is missing, the bond between positions C⁸
30 and C⁹ is a double bond and the bond between positions C⁸ and N⁷ is a
31 single bond;
32 or a pharmaceutically acceptable salt thereof, and a pharmaceuti-
33 cally acceptable inert carrier.

1 Claim 52 (new) A method of treating a mammalian subject
2 in need of treatment for or prevention of stroke, Parkinson's
3 disease, multiple sclerosis, or amyotropic lateral sclerosis which
4 comprises the step of administering to said mammalian subject a
5 therapeutically effective amount of a compound of the Formula (I)
6 as defined in claim 28.

1 Claim 53 (new) A pharmaceutical composition for treating
2 a neurodegenerative disease which comprises a therapeutically
3 effective amount of a compound of the Formula (I)



I

5 wherein

6 R¹ is methyl, formyl, carboxy, cyano, -CH=NOH, -CH=NNHCONH₂, or -CO-
7 NR⁵R⁶, wherein

8 R⁵ and R⁶ independently from each other are hydrogen or
9 lower alkyl or together with the nitrogen atom to which they are
10 attached, form a 5- or 6-membered, saturated or unsaturated hetero-
11 cyclic ring optionally containing one or more further nitrogen ,
12 sulfur and/or oxygen atoms;

13 R² is nitro or amino;

14 R³ is hydrogen, lower alkanoyl, or -CONR⁷R⁸ wherein

15 R⁷ and R⁸ independently from each other are hydrogen,
16 lower alkoxy, lower alkyl, or lower cycloalkyl, or together with

17 the nitrogen atom to which they are attached, form a 5- or 6-
18 membered, saturated or unsaturated heterocyclic ring optionally
19 containing one or more further nitrogen, sulfur and/or oxygen
20 atoms;
21 R⁴ is hydrogen or lower alkyl; and
22 the dotted lines have the following meanings:
23 if R³ and R⁴ are not present, the bond between positions C⁸ and C⁹ is
24 a single bond, and the bond between positions C⁸ and N⁷ is a double
25 bond;
26 if R³ and R⁴ are present, the bonds between positions C⁸ and C⁹ and
27 between positions C⁸ and N⁷ are single bonds; and
28 if R³ is present and R⁴ is missing, the bond between positions C⁸
29 and C⁹ is a double bond and the bond between positions C⁸ and N⁷ is a
30 single bond;
31 or a pharmaceutically acceptable salt thereof, and a pharmaceuti-
32 cally acceptable inert carrier.

1 Claim 54 (new) A method of treating a mammalian subject
2 in need of treatment for a neurodegenerative disease which com-
3 prises the step of administering to said mammalian subject a
4 therapeutically effective amount of a compound of the Formula (I)
5 as defined in claim 28.